INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Portfolio Pulse from
INmune Bio, Inc. plans to submit a Biologics License Application to the FDA for CORDStrom, a treatment for Recessive Dystrophic Epidermolysis Bullosa, following a Type C meeting with the FDA.
February 10, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio plans to submit a BLA to the FDA for CORDStrom, a treatment for RDEB, following a Type C meeting. This step is crucial for regulatory approval and market entry.
The announcement of a BLA submission is a significant milestone for INmune Bio, indicating progress towards regulatory approval. This could positively impact the stock price as it shows advancement in their product pipeline and potential future revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100